Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oral N-acetyl-D-mannosamine - Leadiant Biosciences

Next Previous
Drug Profile

Oral N-acetyl-D-mannosamine - Leadiant Biosciences

Alternative Names: 2-Actamido-2-deoxy-D-mannose; D-ManNAc; DEX-M74; LB-301 - Leadiant Biosciences; LB-701; LB301; ManNAc; N-acetyl-D-mannosamine monohydrate; N-acetyl-mannosamine

Latest Information Update: 28 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Human Genome Research Institute
  • Developer Leadiant Biosciences
  • Class Hexosamines; Small molecules
  • Mechanism of Action Glycosylation stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Nonaka distal myopathy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Nonaka distal myopathy
  • No development reported Kidney disorders

Most Recent Events

  • 28 Apr 2024 No recent reports of development identified for phase-I development in Kidney-disorders in USA (PO)
  • 22 Apr 2022 Phase-III development for Nonaka distal myopathy is ongoing in the US (Leadiant Biosciences pipeline, April 2022)
  • 05 Apr 2022 Leadiant Biosciences and National Human Genome Research Institute initiates the phase II MAGiNE study for Nonaka distal myopathy in USA in February 2020 (PO, Liquid) (NCT04231266)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top